283 related articles for article (PubMed ID: 27897269)
1. An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure.
Vandell AG; Lee J; Shi M; Rubets I; Brown KS; Walker JR
Pharmacogenomics J; 2018 Jan; 18(1):153-159. PubMed ID: 27897269
[TBL] [Abstract][Full Text] [Related]
2. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.
Rakhmanina NY; Neely MN; Van Schaik RH; Gordish-Dressman HA; Williams KD; Soldin SJ; van den Anker JN
Ther Drug Monit; 2011 Aug; 33(4):417-24. PubMed ID: 21743379
[TBL] [Abstract][Full Text] [Related]
3. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms.
Zhou Q; Ruan ZR; Jiang B; Yuan H; Zeng S
Pharmazie; 2013 Feb; 68(2):124-8. PubMed ID: 23469684
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporine markedly raises the plasma concentrations of repaglinide.
Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
[TBL] [Abstract][Full Text] [Related]
5. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic Analysis of OATP1B1, UGT1A1, and BCRP Variants in Relation to the Pharmacokinetics of Letermovir in Previously Conducted Clinical Studies.
Kobie J; Guo Z; Cho CR; Menzel K; McCrea JB; Blanchard R; Shaw PM
J Clin Pharmacol; 2019 Sep; 59(9):1236-1243. PubMed ID: 31022310
[TBL] [Abstract][Full Text] [Related]
7. Association between SLCO1B1 genetic polymorphisms and bleeding risk in patients treated with edoxaban.
Han JM; Jang EJ; Yee J; Song TJ; Kim DH; Park J; Gwak HS
Sci Rep; 2023 Sep; 13(1):15967. PubMed ID: 37749323
[TBL] [Abstract][Full Text] [Related]
8. Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin.
Niemi M; Kivistö KT; Diczfalusy U; Bodin K; Bertilsson L; Fromm MF; Eichelbaum M
Pharmacogenet Genomics; 2006 Aug; 16(8):565-8. PubMed ID: 16847425
[TBL] [Abstract][Full Text] [Related]
9. Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2.
Ferrari M; Guasti L; Maresca A; Mirabile M; Contini S; Grandi AM; Marino F; Cosentino M
Eur J Clin Pharmacol; 2014 May; 70(5):539-47. PubMed ID: 24595600
[TBL] [Abstract][Full Text] [Related]
10. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.
Weiner M; Peloquin C; Burman W; Luo CC; Engle M; Prihoda TJ; Mac Kenzie WR; Bliven-Sizemore E; Johnson JL; Vernon A
Antimicrob Agents Chemother; 2010 Oct; 54(10):4192-200. PubMed ID: 20660695
[TBL] [Abstract][Full Text] [Related]
11. Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.
Choi HY; Bae KS; Cho SH; Ghim JL; Choe S; Jung JA; Jin SJ; Kim HS; Lim HS
Pharmacogenet Genomics; 2015 Dec; 25(12):595-608. PubMed ID: 26367500
[TBL] [Abstract][Full Text] [Related]
12. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
Niemi M; Backman JT; Kajosaari LI; Leathart JB; Neuvonen M; Daly AK; Eichelbaum M; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2005 Jun; 77(6):468-78. PubMed ID: 15961978
[TBL] [Abstract][Full Text] [Related]
13. The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition.
Jiang F; Choi JY; Lee JH; Ryu S; Park ZW; Lee JG; Na HS; Lee SY; Oh WY; Chung MW; Choi SE
Pharmacogenomics; 2017 Apr; 18(5):459-469. PubMed ID: 28350522
[TBL] [Abstract][Full Text] [Related]
14. Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects.
Ulvestad M; Skottheim IB; Jakobsen GS; Bremer S; Molden E; Asberg A; Hjelmesæth J; Andersson TB; Sandbu R; Christensen H
Clin Pharmacol Ther; 2013 Mar; 93(3):275-82. PubMed ID: 23361102
[TBL] [Abstract][Full Text] [Related]
15. Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex.
Prasad B; Evers R; Gupta A; Hop CE; Salphati L; Shukla S; Ambudkar SV; Unadkat JD
Drug Metab Dispos; 2014 Jan; 42(1):78-88. PubMed ID: 24122874
[TBL] [Abstract][Full Text] [Related]
16. The Influence of MDR1 G2677T/a genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers.
Xiang Q; Cui YM; Zhao X; Yan L; Zhou Y
Pharmacology; 2012; 89(1-2):105-10. PubMed ID: 22398664
[TBL] [Abstract][Full Text] [Related]
17. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.
Chigutsa E; Visser ME; Swart EC; Denti P; Pushpakom S; Egan D; Holford NH; Smith PJ; Maartens G; Owen A; McIlleron H
Antimicrob Agents Chemother; 2011 Sep; 55(9):4122-7. PubMed ID: 21709081
[TBL] [Abstract][Full Text] [Related]
18. Rapid identification of three functionally relevant polymorphisms in the OATP1B1 transporter gene using Pyrosequencing.
Rohrbacher M; Kirchhof A; Skarke C; Geisslinger G; Lötsch J
Pharmacogenomics; 2006 Mar; 7(2):167-76. PubMed ID: 16515396
[TBL] [Abstract][Full Text] [Related]
19. Edoxaban transport via P-glycoprotein is a key factor for the drug's disposition.
Mikkaichi T; Yoshigae Y; Masumoto H; Imaoka T; Rozehnal V; Fischer T; Okudaira N; Izumi T
Drug Metab Dispos; 2014 Apr; 42(4):520-8. PubMed ID: 24459178
[TBL] [Abstract][Full Text] [Related]
20. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics.
Katz DA; Carr R; Grimm DR; Xiong H; Holley-Shanks R; Mueller T; Leake B; Wang Q; Han L; Wang PG; Edeki T; Sahelijo L; Doan T; Allen A; Spear BB; Kim RB
Clin Pharmacol Ther; 2006 Mar; 79(3):186-96. PubMed ID: 16513443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
